| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000029369 |
| Receipt No. | R000033564 |
| Scientific Title | Relationship between family expressed emotion (EE) and symptomatic relapse in premenstrual syndrome (PMS) /premenstrual dysphoric disorder (PMDD) patients |
| Date of disclosure of the study information | 2017/10/01 |
| Last modified on | 2021/02/24 (Ver. 4) |
| Basic information | ||
| Public title | Relationship between family expressed emotion (EE) and symptomatic relapse in premenstrual syndrome (PMS) /premenstrual dysphoric disorder (PMDD) patients | |
| Acronym | EE and symptomatic relapse in PMS/PMDD | |
| Scientific Title | Relationship between family expressed emotion (EE) and symptomatic relapse in premenstrual syndrome (PMS) /premenstrual dysphoric disorder (PMDD) patients | |
| Scientific Title:Acronym | EE and symptomatic relapse in PMS/PMDD | |
| Region |
|
|
| Condition | ||
| Condition | Premenstrual syndrome and premenstrual dysphoric disorder | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To confirm the hypothesis that high EE of a family member/partner is associated with higher risk of symptomatic relapse after achieving remission in PMS/PMDD patient. |
| Basic objectives2 | Others |
| Basic objectives -Others | association study |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Relapse-free survival |
| Key secondary outcomes | Change in PMS/PMDD symptoms assessed by Penn Daily Symptom Report (DSR) score.
Subjective change in symptoms, improvements in understanding of disease, subjective change in communication with family member/partner at the end of the study period. Change in EE of family member/partner assessed by Five Minute Speech Sample (FMSS) since first assessment. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | Patient and family member/partner who have come to our hospital during the study period and meet all of the following criteria.
[PMS/PMDD patient] 1. Agrees to be treated for PMS/PMDD 2. Has PMS/PMDD symptoms according to DSR and Sheehan Disability Scale (SDISS) (Pre-menstrual SDR score of 80 and above, score is increased by more than 50% of the post-menstrual score, and meets 1 or more items in SDISS) 3. Is above 20 years old and under 40 years old at the time of agreement 4. Has a regular menstrual cycle (Menstrual cycle is between 25 and 38 days and fluctuation is 7 days or less, duration of bleeding is within 7 days and fluctuation is 2 days or less) 5. Has a family member/partner who has lived in the same household for more than 3 months prior to agreement to participate in the study, who plans to live in the same household until the end of the study, and who is willing to attend the outpatient sessions 6. Is able to sign the agreement form by free will (both the patient and family member/partner) [Family member/partner] 1. Is a family member/partner of the patient who meets the inclusion criteria |
|||
| Key exclusion criteria | [PMS/PMDD patient]
1. Meets the diagnostic criteria of schizophrenia, depression, or drug/medication-induced depression according to DSM-5 or has a history of mania episode and meets the diagnostic criteria for bipolar disorder 2. Requires continued intake of oral contraceptives and/or other hormonal agents 3. Requires steroids and/or other anti-inflammatory medications 4. Possess hypothyroidism, Cushing Disease, systemic lupus erythematosus or any other disease which has risk for depressive symptoms 5. Any patients whom the study staff or investigator find inappropriate to include in the study [Family member/partner] None |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Shiga University of Medical Science | ||||||
| Division name | Department of Psychiatry | ||||||
| Zip code | |||||||
| Address | Seta Tsukinowa-cho, Otsu, Shiga | ||||||
| TEL | 077-548-2111 | ||||||
| kaoi0211@belle.shiga-med.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Shiga University of Medical Science | ||||||
| Division name | Department of Psychiatry | ||||||
| Zip code | |||||||
| Address | Seta Tsukinowa-cho, Otsu, Shiga | ||||||
| TEL | 077-548-2111 | ||||||
| Homepage URL | |||||||
| kenichik@belle.shiga-med.ac.jp | |||||||
| Sponsor | |
| Institute | Shiga University of Medical Science |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Society for the Promotion of Science
|
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 0 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Investigate the relationship between EE of a family member/partner assessed by FMSS and symptomatic relapse in PMS/PMDD patient assessed by DSR score. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033564 |